Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review

Australasian Physical and Engineering Sciences in Medicine

Volumn 38, Issue 1, 2015, Pages 7-22

  Chalkia, M T ^a   Stefanoyiannis, A P ^a   Chatziioannou, S N ^a   Round, W H ^b   Efstathopoulos, E P ^a   Nikiforidis, G C ^c  

^a KAT HOSPITAL   (Greece)

^b UNIVERSITY OF WAIKATO   (New Zealand)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

111In DTPA octreotide; 177Lu DOTATATE; 90Y DOTATOC; Neuroendocrine tumours; Patient specific dosimetry; Peptide receptor radionuclide therapy

Indexed keywords

DOSIMETRY; IMAGE ACQUISITION; PEPTIDES; RADIOISOTOPES; TUMORS;

INTERNAL IRRADIATION; INTERNAL RADIATION DOSE; OCTREOTIDE; PATIENT SPECIFIC; PEPTIDE RECEPTOR; RADIONUCLIDE THERAPY; SOMATOSTATIN RECEPTORS; THERAPEUTIC EFFECTS;

PATIENT TREATMENT;

GALLIUM 68; INDIUM 111; LUTETIUM 177; OCTREOTIDE TYROSINE TETRAXETAN Y 90; OCTREOTIDE TYROSINE THREONINE TETRAXETAN LU 177; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG; YTTRIUM 86; OCTREOTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

BONE MARROW TOXICITY; CANCER RADIOTHERAPY; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; ISOTOPE LABELING; LEUKEMIA; LIVER TOXICITY; MEASUREMENT ACCURACY; MEASUREMENT ERROR; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOACTIVITY; RADIOISOTOPE DISTRIBUTION; REVIEW; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; METABOLISM; PERSONALIZED MEDICINE; RADIOMETRY; SCINTISCANNING;

HUMANS; NEUROENDOCRINE TUMORS; OCTREOTIDE; PRECISION MEDICINE; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 84930503953     PISSN: 01589938     EISSN: 18795447     Source Type: Journal    
DOI: 10.1007/s13246-014-0312-7     Document Type: Review

References (84)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072. doi:10.1200/JCO.2007.15.4377
2. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (2010) The pathologic classification of neuroendocrine tumors. A review of nomenclature, grading, and staging systems. Pancreas 39:707–712. doi:10.1097/MPA.0b013e3181ec124e
3. Bodei L (2008) Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Dissertation, University Medical Center Groningen
4. Novartis Oncology (2014) Multifaceted cancer that benefits from multidisciplinary care. http://www.neuroendocrinetumor.com/health-care-professional/managing-nets.jsp. Accessed on 29 March 2014
5. Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, O’Dorisio MS, O’Dorisiol TM, Howe JR, Cremonesi M et al (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40:800–816. doi:10.1007/s00259-012-2330-6
6. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, Pauwels S (2005) Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose–effect relationship. J Nucl Med 46:99S–106S
7. 86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT487): a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30:510–518. doi:10.1007/s00259-003-1117-1
8. Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, Teunissen JJ, de Jong M, van Lom K, de Herder WW et al (2009) Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging 36:1138–1146. doi:10.1007/s00259-009-1072-6
9. Boerman OC, Oyen WJ, Corstens FH (2001) Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med 28:1447–1449
10. Konijnenberg MW (2003) Is the renal dosimetry for [90Y-DOTA0, Tyr3]Octreotide accurate enough to predict thresholds for individual patients? Cancer Biother Radiopharm 18:619–625
11. Sandström M, Garske U, Granberg D, Sundin A, Lundqvist HU (2010) Individualized dosimetry in patients undergoing therapy with (177)Lu- DOTA-D-Phe(1)-Tyr(3)-octreotate. Eur J Nucl Med Mol Imaging 37:212–225. doi:10.1007/s00259-009-1216-8
12. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, Jamar F, Pauwels S et al (1999) Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 10:S23–S29
13. Shen S, DeNardo GL, DeNardo SJ (1994) Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys 21:1409–1417
14. Öberg K (2012) Molecular imaging and radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2:448–458
15. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, Robertson JS, Howell RW, Wessels BW, Fisher DR et al (1999) MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40:37S–61S
16. Stabin MG (1996) MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37:538–546
17. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023–1027
18. Sjögreen K, Ljungberg M, Wingårdh K, Minarik D, Strand SE (2005) The LundADose method for planar image activity quantification and absorbed-dose assessment in radionuclide therapy. Cancer Biother Radiopharm 20:92–97
19. Philips imalytics (2014) Research Dosimetry Solution- STRATOS and STRATOS+. http://www.imalytics.philips.com/sites/philipsimalytics/products/dosimetry/dosimetry.page. Accessed on 10 March 2014
20. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58:437–441
21. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP (2010) Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 17:R53–R73. doi:10.1677/ERC-09-0078
22. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli GM (2006) Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 47:1467–1475
23. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW et al (2002) Phase I study of peptide receptor radionuclide therapy with [In-DTPA]-octreotide: the Rotterdam experience. Semin Nucl Med 32:110–122
24. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12:941–945
25. 90Y-DOTATOC. J Nucl Med 43:610–616
26. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 3:207–216. doi:10.1007/s00259-002-1023-y
27. Valkema R, Pauwels S, Kvols L, Jamar F, Barone R, Bakker WH, Lasher J, Krenning EP (2003) Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with [90Y-DOTA0, Tyr3]-octreotide in patients with somatostatin receptor positive tumours. [abstract]. Eur J Nucl Med Mol Imaging 30:S232
28. de Jong M, Krenning EP (2002) New advances in peptide receptor radionuclide therapy. J Nucl Med 43:617–620
29. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, Herder WW, Feelders RA, Eijck CHJ, Jong M, Srinivasan A et al (2003) Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging 30:417–422. doi:10.1007/s00259-002-1050-8
30. 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging 38:2125–2135. doi:10.1007/s00259-011-1902-1
31. 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 38:302–311. doi:10.1007/s00259-010-1631-x
32. 177Lu-DOTATATE for advanced pancreatic neuroendocrine tumors. Neuroendocrinology 97:347–354. doi:10.1159/000348394
33. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH et al (2005) Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. J Nucl Med 46:83S–91S
34. Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, Krenning EP, Jamar F (2005) Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs. J Nucl Med 46:92S–98S
35. 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 40:762–767
36. 90Y-DOTATOC. Eur J Nucl Med 26:877–886
37. 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31:1257–1262. doi:10.1007/s00259-004-1553-6
38. Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C, Rossi A, Bartolomei M, Mei R, Severi SF et al (2010) Dosimetry for treatment with radiolabelled somatostatin analogues. A review. J Nucl Med Mol Imaging 54:37–51
39. 111In-DTPA-octreotide. Eur J Nucl Med 28:1743–1750. doi:10.1007/s002590100628
40. 111In-labelled octreotide derivatives. Eur J Nucl Med 27:1318–1325. doi:10.1007/s002590000289
41. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience. Eur J Nucl Med Mol Imaging 33:1123–1133. doi:10.1007/s00259-006-0113-7
42. 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs. J Nucl Med 49:1060–1065. doi:10.2967/jnumed.107.046961
43. Snyder WS, Ford MR, Warner GG, Watson SB (1975) S” absorbed dose per unit cumulated activity for selected radionuclides and organs. Mird pamphlet no.11. Society of Nuclear Medicine, New York
44. Snyder WS, Ford, Warner GG (1978) Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. Mird PAMPHLET No. 5 Revised. Society of Nuclear Medicine, New York
45. Stabin MG, Siegel JA (2003) Physical models and dose factors for use in internal dose assessment. Health Phys 85:294–310
46. Stabin MG, Emmons MA, Segars WP, Fernald MJ (2009) The Vanderbilt University reference adult and pediatric phantom series. In: Xu XG (ed) Handbook of anatomical models for radiation dosimetry. Taylor & Francis, Philadelphia, pp 337–346
47. Stabin MG (2008) Update: the case for patient-specific dosimetry in radionuclide therapy. Cancer Biother Radiopharm 23:273–284. doi:10.1089/cbr.2007.0445
48. Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, LoBuglio AF (2002) Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. J Nucl Med 43:1245–1253
49. Council Directive 97/43/EURATOM (1997)
50. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31:1386–1392. doi:10.1007/s00259-004-1561-6
51. Garkavij M, Nickel M, Sjögreen-Gleisner K, Ljungberg M, Ohlsson T, Wingårdh K, Strand SE, Tennvall J (2010) 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer 116:1084–1092. doi:10.1002/cncr.24796
52. Hindorf C, Glatting G, Chiesa C, Lindén O, Flux G (2010) EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging 37:1238–1250. doi:10.1007/s00259-010-1422-4
53. Clairand I, Ricard M, Gouriou J, Di Paola M, Aubert B (1999) DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry. J Nucl Med 40:1517–1523
54. Medicinsk strålningsfysik, Lund (2014) LundaDose program. http://www.msf.lu.se/forskning/nuclear-medicine-group/lundadose-program. Accessed on 19 Sept 2014
55. 3-octreotide. Nucl Med Commun 29:283–290
56. 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 44:708–716
57. 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits. Appl Radiat Isot 64:792–797
58. 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors. J Nucl Med 52:1474–1481. doi:10.2967/jnumed.111.088203
59. 99mTc-HYNIC-Tyr3-Octreotide in patients with neuroendocrine tumours. Annual Congress of the European Association of Nuclear Medicine, Lyon. http://www.eanm13.eanm.org/abstracts/abstract_search_result.php?navId=25
60. 90Y-labeled somatostatin analogs. J Nucl Med 46:13S–17S
61. 177Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 30:1100–1106. doi:10.1200/JCO.2011.37.2151
62. 177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging 38:1788–1797. doi:10.1007/s00259-011-1833-x
63. Berker Y, Goedicke A, Kemerink GJ, Aach T, Schweizer B (2011) Activity quantification combining conjugate-view planar scintigraphies and SPECT/CT data for patient-specific 3-D dosimetry in radionuclide therapy. Eur J Nucl Med Mol Imaging 38:2173–2185. doi:10.1007/s00259-011-1889-7
64. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122
65. Shen S, DeNardo GL, Yuan A, DeNardo DA, DeNardo SJ (1994) Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med 35:1381–1389
66. Ito S, Kurosawa H, Kasahara H, Teraoka S, Ariga E, Deji S, Hirota M, Saze T, Minamizawa T, Nishizawa K (2009) (90)Y bremsstrahlung emission computed tomography using gamma cameras. Ann Nucl Med 23:257–267. doi:10.1007/s12149-009-0233-9
67. Minarik D, Sjögreen Gleisner K, Ljungberg M (2008) Evaluation of quantitative (90)Y SPECT based on experimental phantom studies. Phys Med Biol 53:5689–5703. doi:10.2967/jnumed.110.079897
68. 90Y PET. J Nucl Med 51:1969–1973. doi:10.2967/jnumed.110.080093
69. 90Y bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy. J Nucl Med 51:1974–1978. doi:10.2967/jnumed.110.079897
70. Selwyn RG, Nickles RJ, Thomadsen BR, DeWerd LA, Micka JA (2007) A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr. Appl Radiat Isot 65:318–327
71. Lhommel R, van Elmbt L, Goffette P, Van den Eynde M, Jamar F, Pauwels S, Walrand S (2010) Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres. Eur J Nucl Med Mol Imaging 37:1654–1662. doi:10.1007/s00259-010-1470-9
72. 111In-DTPA]octreotide. J Nucl Med 45:1168–1171
73. Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA, Clairand I, Sgouros G (2003) MIRD pamphlet No. 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med 44:1113–1147
74. Siegel JA, Stabin MG, Sharkey RM (2010) Renal dosimetry in peptide radionuclide receptor therapy. Cancer Biother Radiopharm 25:581–588. doi:10.1089/cbr.2010.0805
75. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]Octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36:147–156. doi:10.1053/j.semnuclmed.2006.01.001
76. 90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 29:2416–2423. doi:10.1200/JCO.2010.33.7873
77. 111In-DTPA-D-Phe1- octreotide infusions after catheterization of the hepatic artery. J Nucl Med 47:1476–1482
78. 3-octreotide: the experience of the European institute of oncology group. Semin Nucl Med 32:141–147. doi:10.1053/snuc.2002.31563
79. 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 33:532–540. doi:10.1007/s00259-005-0020-3
80. 90Y-DOTATOC therapies in patients with neuroendocrine tumors. Cancer Biother Radiopharm 22:130–135. doi:10.1089/cbr.2007.306
81. 90Y-DOTATOC PRRT. J Nucl Med 49:322P
82. 177Lu- DOTA-Octreotate treatment. J Nucl Med 54:33–41. doi:10.2967/jnumed.112.107524
83. 177Lu-DOTATATE. Clin Nucl Med 38:188–194. doi:10.1097/RLU.0b013e3182814ac1
84. 177Lu-DOTATOC. Recent Results Cancer Res 194:519–536. doi:10.1007/978-3-642-27994-2_30